Q1 EPS Estimate for Beam Therapeutics Reduced by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Equities research analysts at Wedbush decreased their Q1 2025 earnings estimates for Beam Therapeutics in a research note issued on Tuesday, February 25th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.21) per share for the quarter, down from their previous forecast of ($1.16). Wedbush currently has a “Outperform” rating and a $57.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.81) EPS, FY2026 earnings at ($5.60) EPS, FY2027 earnings at ($5.42) EPS and FY2028 earnings at ($4.15) EPS.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, beating the consensus estimate of ($1.25) by $0.16. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The business had revenue of $30.00 million for the quarter, compared to the consensus estimate of $16.47 million. During the same period in the prior year, the company posted $1.73 earnings per share. Beam Therapeutics’s revenue was down 90.5% compared to the same quarter last year.

Other equities analysts also recently issued reports about the stock. Leerink Partnrs upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Royal Bank of Canada increased their price objective on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a research note on Wednesday. Cantor Fitzgerald upgraded shares of Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research note on Wednesday, January 29th. Sanford C. Bernstein upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, Leerink Partners upgraded shares of Beam Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $27.00 to $39.00 in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $47.89.

Beam Therapeutics Stock Performance

BEAM stock opened at $27.89 on Thursday. The company’s 50-day simple moving average is $27.19 and its 200 day simple moving average is $25.89. Beam Therapeutics has a 52 week low of $20.84 and a 52 week high of $49.50. The company has a market capitalization of $2.31 billion, a PE ratio of -15.85 and a beta of 1.92.

Insider Activity at Beam Therapeutics

In related news, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the transaction, the chief executive officer now owns 908,659 shares in the company, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total transaction of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Horizon Kinetics Asset Management LLC raised its holdings in Beam Therapeutics by 4.4% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 9,597 shares of the company’s stock worth $238,000 after purchasing an additional 403 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Beam Therapeutics by 6.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company’s stock worth $198,000 after buying an additional 496 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Beam Therapeutics by 2.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,396 shares of the company’s stock valued at $524,000 after purchasing an additional 516 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Beam Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,981 shares of the company’s stock valued at $75,000 after purchasing an additional 524 shares during the period. Finally, Martingale Asset Management L P grew its position in Beam Therapeutics by 8.6% in the 4th quarter. Martingale Asset Management L P now owns 11,438 shares of the company’s stock valued at $284,000 after purchasing an additional 909 shares during the period. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.